Poolbeg Pharma (POLB) Competitors GBX 4.14 -0.26 (-5.91%) As of 11:44 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesBuy This Stock POLB vs. TILS, VSN, SCLP, MPH, IMM, ORPH, HVO, REDX, ETX, and HEMOShould you be buying Poolbeg Pharma stock or one of its competitors? The main competitors of Poolbeg Pharma include Tiziana Life Sciences (TILS), Verseon (VSN), Scancell (SCLP), Mereo BioPharma Group plc (MPH.L) (MPH), ImmuPharma (IMM), Open Orphan (ORPH), hVIVO (HVO), Redx Pharma (REDX), e-therapeutics (ETX), and Hemogenyx Pharmaceuticals (HEMO). These companies are all part of the "biotechnology" industry. Poolbeg Pharma vs. Its Competitors Tiziana Life Sciences Verseon Scancell Mereo BioPharma Group plc (MPH.L) ImmuPharma Open Orphan hVIVO Redx Pharma e-therapeutics Hemogenyx Pharmaceuticals Tiziana Life Sciences (LON:TILS) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has stronger earnings & valuation, TILS or POLB? Tiziana Life Sciences has higher earnings, but lower revenue than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life Sciences-£3.60M0.00N/A-£16.30N/APoolbeg PharmaN/AN/A-£4.50B-£0.01-356.90 Do insiders & institutionals have more ownership in TILS or POLB? 0.6% of Poolbeg Pharma shares are held by institutional investors. 7.6% of Poolbeg Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is TILS or POLB more profitable? Tiziana Life Sciences' return on equity of 0.00% beat Poolbeg Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Poolbeg Pharma N/A -32.56%-21.33% Does the media prefer TILS or POLB? In the previous week, Tiziana Life Sciences' average media sentiment score of 1.25 beat Poolbeg Pharma's score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Overall Sentiment Tiziana Life Sciences Positive Poolbeg Pharma Neutral SummaryTiziana Life Sciences and Poolbeg Pharma tied by winning 4 of the 8 factors compared between the two stocks. Get Poolbeg Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for POLB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding POLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart POLB vs. The Competition Export to ExcelMetricPoolbeg PharmaBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£28.86M£233.65M£5.69B£2.57BDividend YieldN/A3.78%5.72%5.30%P/E Ratio-356.9040.9775.865,413.34Price / SalesN/A4,769.70489.9296,831.90Price / Cash2.1113.1925.8127.93Price / Book0.00118.2112.848.43Net Income-£4.50B-£90.99M£3.28B£5.89B7 Day Performance-3.72%1.14%0.20%0.35%1 Month Performance38.79%20.13%4.59%44.36%1 Year Performance-60.81%641.82%68.31%164.68% Poolbeg Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)POLBPoolbeg PharmaN/AGBX 4.14-5.9%N/A-59.0%£28.86MN/A-356.9012TILSTiziana Life SciencesN/AN/AN/AN/A£113.85M-£3.60M-3.5911Positive NewsVSNVerseonN/AN/AN/AN/A£112.24MN/A-5.17N/AGap UpSCLPScancellN/AGBX 9.15+2.8%N/A-43.6%£94.96MN/A-439.9051News CoverageEarnings ReportInsider TradeHigh Trading VolumeMPHMereo BioPharma Group plc (MPH.L)N/AN/AN/AN/A£89.76MN/A-0.2150Gap DownIMMImmuPharmaN/AGBX 13.98+28.8%N/A+1,026.1%£69.86MN/A-1,570.6713Trending NewsGap UpHigh Trading VolumeORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179HVOhVIVO1.8008 of 5 starsGBX 9.70+0.5%GBX 28+188.7%-67.1%£66.66M£62.73M625.81N/AREDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeHEMOHemogenyx PharmaceuticalsN/AGBX 1,010+9.7%N/A+79,553.9%£47.74MN/A-557.7014News CoverageGap Up Related Companies and Tools Related Companies TILS Competitors VSN Competitors SCLP Competitors MPH Competitors IMM Competitors ORPH Competitors HVO Competitors REDX Competitors ETX Competitors HEMO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:POLB) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredFanatics Hit $31B-Is This Nasdaq Next?Fanatics built an empire by owning the fan experience-scaling to a $31B valuation. But the next wave isn't abo...i2i Marketing Group, LLC | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored$4?In times like these… it’s almost impossible to find a good deal. That’s why you should check this out. G...Monument Traders Alliance | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poolbeg Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Poolbeg Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free POLB Stock Alerts